Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (ACIU) is a Swiss clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases like Alzheimer's. This page provides investors and researchers with centralized access to official news, financial disclosures, and scientific developments directly from the company.
Key resources include earnings reports, clinical trial updates, strategic collaborations, and regulatory milestones. Stay informed on ACIU's progress in developing diagnostic tools and therapies targeting protein misfolding pathologies through its proprietary platforms.
Content spans pipeline advancements, peer-reviewed research highlights, and material business events. Bookmark this page to efficiently track ACIU's contributions to neuroscience innovation and make data-driven decisions based on verified company communications.
AC Immune SA (NASDAQ: ACIU) has published findings in JAMA Neurology demonstrating the safety and immunogenicity of its ACI-24 anti-Abeta vaccine in individuals with Down syndrome (DS). This Phase 1b trial showed a positive immune response without serious adverse effects, indicating the vaccine's potential for future Alzheimer’s disease interventions. An optimized formulation is set to enter further clinical testing this year, reinforcing AC Immune's commitment to addressing neurodegenerative diseases.
AC Immune, a clinical-stage biopharmaceutical company, reported Q1 2022 results highlighting key advancements in neurodegenerative disease treatments. They announced favorable interim data from the ACI-35.030 anti-pTau vaccine, showcasing strong immunogenicity and safety. Additionally, the ACI-12589 PET tracer provided first images of alpha-synuclein in human brains, critical for diagnosing MSA. With a solid cash position of CHF 173.8 million, the company remains funded through at least Q1 2024, expecting five more clinical readouts by year's end to boost value creation.
AC Immune SA (NASDAQ: ACIU) announced its participation in the B.Riley Annual Neuro & Ophthalmology Virtual Investor Conference on April 27-28, 2022. CEO Prof. Andrea Pfeifer will host a Fireside chat on April 28 at 11:30 am EDT, discussing the company's development pipeline for neurodegenerative diseases and upcoming clinical milestones. Having achieved two milestones in Q1, AC Immune will present five more data readouts this year, highlighting its precision medicine approach. The webcast will be available on the company's website.
AC Immune SA (NASDAQ: ACIU) announces significant management changes, appointing Howard Donovan as Chief HR Officer and promoting Chris Roberts to Interim CFO, due to Joerg Hornstein's departure. Donovan brings extensive HR experience from the World Economic Forum, while Roberts has a strong finance background, essential for AC Immune's financial operations. Julian Snow is also promoted to Vice President, U.S. Finance & Corporate Development. The changes aim to strengthen the company's internal functions as it continues to develop precision medicine for neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU) announced the clinical validation of its a-syn PET tracer, ACI-12589, which distinguishes multiple system atrophy (MSA) from other a-synucleinopathies. This groundbreaking development, presented by Dr. Oskar Hansson, shows ACI-12589's potential in enabling targeted therapeutics and diagnostics for neurodegenerative diseases. With two validated technology platforms and a robust pipeline, AC Immune aims to accelerate therapeutic development. The company expects seven clinical data readouts in 2022, highlighting its commitment to precision medicine.
AC Immune reported significant progress in its clinical pipeline for neurodegenerative diseases, highlighting seven expected clinical data readouts in 2022. The company has advanced three vaccines targeting Tau, Abeta, and alpha-synuclein. Financially, AC Immune boasts a robust cash position of CHF 198.2 million, ensuring operations through Q1 2024. The net loss for 2021 increased to CHF 73.0 million from CHF 61.9 million in 2020. Moreover, the company anticipates total cash burn between CHF 75 million and CHF 80 million for 2022.
AC Immune SA (NASDAQ: ACIU) will host a webinar on March 29 at 10:00 AM ET to discuss alpha-synuclein in neurodegenerative diseases. KOL Oskar Hansson, MD, PhD, from Skåne University Hospital, will present the significance of biomarkers in Alzheimer’s and alpha-synucleinopathies, alongside AC Immune's clinical data on their PET tracer. The company will also outline its a-syn targeted therapeutic and diagnostic candidates, advancing precision medicine for diseases like Parkinson's. A Q&A session will follow the presentation.
AC Immune SA (NASDAQ: ACIU) announced positive proof-of-concept data for its experimental a-syn PET tracer, ACI-12589, in diagnosing Multiple System Atrophy (MSA). Conducted by Lund University, the trial showcased the ability to distinguish MSA patients from healthy individuals and other a-synucleinopathies. Dr. Oskar Hansson highlighted the breakthrough as a significant clinical advancement. The results were presented at the AD/PD Conference in Barcelona and indicate enhanced specificity and target engagement. A webinar on March 29 will further discuss these findings.
AC Immune (NASDAQ: ACIU) announced five data presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM) from March 15-20, 2022, showcasing its focus on neurodegenerative diseases. Prof. Andrea Pfeifer, CEO, highlighted a significant milestone: the first in-human study of the ACI-12589 a-syn PET tracer. This research aims to enhance disease detection and prevention strategies through precision medicine. These presentations underline the company's commitment to advancing treatments for neurodegenerative diseases, potentially impacting future market performance.
AC Immune SA (NASDAQ: ACIU) revealed new interim data from its Phase 1b/2a trial for ACI-35.030, a pioneering pTau vaccine for early Alzheimer's disease. Findings show significant antibody induction specific to pathological pTau, with a favorable safety profile noted in all dosage cohorts. The study has been expanded to 24 participants to gather more data. CEO Andrea Pfeifer stated these results support ongoing late-stage development, potentially reshaping AD treatment towards earlier interventions alongside advanced diagnostics.
FAQ
What is the current stock price of AC Immune (ACIU)?
What is the market cap of AC Immune (ACIU)?
